Skip to main content
PIRAMAL PHARMA LIMITED logo

PIRAMAL PHARMA LIMITED — Investor Relations & Filings

Ticker · PPLPHARMA ISIN · INE0DK501011 LEI · 3358006D6AL7PZ4U9T51 BSE.NS Manufacturing
Open in API
Filings indexed 367 across all filing types
Latest filing 2023-10-18 Regulatory Filings
Country IN India
Listing BSE.NS PPLPHARMA

About PIRAMAL PHARMA LIMITED

https://www.piramalpharma.com/

Piramal Pharma Limited provides a broad range of products and services across the drug lifecycle through three main business segments: Piramal Pharma Solutions, Piramal Critical Care, and Consumer Healthcare. Piramal Pharma Solutions operates as an integrated Contract Development and Manufacturing Organization (CDMO), offering end-to-end services from drug discovery and development to commercial manufacturing of APIs and formulations. Piramal Critical Care focuses on complex hospital generics, holding a significant global market share in inhalation anesthetics, including Sevoflurane and Isoflurane, as well as injectable anesthesia and pain management therapies. The Consumer Healthcare division manages a diverse portfolio of over-the-counter brands such as Saridon, Lacto Calamine, and Tetmosol. The company leverages an extensive global manufacturing network to deliver specialized healthcare solutions worldwide.

Recent filings

Filing Released Lang Actions
Board Meeting — PIRAMAL PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 27-Oct-2023 to inter-alia consider and approve the Unaudited Financial results of the Company for th…
Regulatory Filings
2023-10-18 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a short announcement dated 18th October 2023 from Piramal Pharma Limited addressed to stock exchanges (BSE and NSE). It references Regulation 29 and 50 of the SEBI Listing Regulations and informs about an upcoming Board meeting on 27th October 2023 to consider and approve the unaudited financial results for the quarter and half year ended 30th September 2023. The document also mentions the closure of the trading window. The length is only 1702 characters, which is quite short and does not contain any actual financial data or detailed financial statements. It is an announcement about the timing and agenda of a board meeting to approve financial results, not the financial results report itself. According to the MENU VS MEAL RULE, this is a report publication announcement or a regulatory filing. Since it is a formal regulatory announcement to stock exchanges about the board meeting and financial results approval, it fits best under Regulatory Filings (RNS).
2023-10-18 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the launch of a new high-throughput screening facility at Piramal Pharma Limited's Ahmedabad site. It provides details about the new capabilities, investment, and strategic benefits to customers. There are no financial statements, regulatory certifications, voting results, or management changes. The document is not a report but an announcement of a business update. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The content is clearly a press release about a business development, which aligns best with the category Capital/Financing Update (CAP) as it discusses a multi-million dollar investment and expansion of capabilities, which is a capital expenditure update.
2023-10-16 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short disclosure letter addressed to stock exchanges about the successful closure of a US FDA inspection at a manufacturing facility. It mentions regulatory compliance and inspection results but does not contain any financial data, detailed report, or management discussion. The length is only 1716 characters, which is quite short and fits the pattern of a regulatory announcement rather than a full report. There is no indication of financial statements or detailed analysis. Therefore, this document is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2023-09-28 English
Updates
Capital/Financing Update Classification · 95% confidence The document is an official intimation to stock exchanges regarding the meeting and decisions of the Committee of Directors related to a Rights Issue and the allotment of equity shares. It references regulatory compliance under SEBI Listing Regulations and details the allotment of shares, increase in paid-up capital, and approval dates. The content is focused on capital raising activities and share allotment, not a full financial report or earnings release. The document length is short (2424 characters) and it is an announcement of a capital/financing event rather than a detailed report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-09-27 English
Updates
Regulatory Filings Classification · 95% confidence The document is an intimation under Regulation 30 of the SEBI Listing Regulations regarding the voluntary liquidation of a step-down wholly-owned subsidiary, Piramal Pharma Japan GK. It provides details as required by SEBI regulations, including financial contribution of the subsidiary and other related information. The document is a regulatory announcement informing the stock exchanges about a corporate event (liquidation of a subsidiary). It does not contain financial statements, audit information, or detailed management discussion. It is not a full report but a regulatory filing to comply with disclosure obligations under SEBI Listing Regulations. The document length is 3416 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-09-12 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.